Elucid, a medical technology company, named Scott Burger as its next chief commercial officer Thursday morning.

Burger, a veteran of the medical device technology space for more than 15 years, most recently served as chief commercial officer of CorVista Health, a non-invasive cardiovascular diagnostic SaaS company, for just over two years. 

Before that, Burger was commercial VP at HeartFlow, a cardiovascular-focused med tech company and held various roles at Johnson & Johnson’s cardiovascular group as well as superDimension, Bard and ConvaTec.  

Over the course of his career, Burger has led investment rounds for a few software-based med tech startups, accruing more than $500 million in funding through these efforts.

In the new position, Burger will be tasked with supporting the company’s expansion plans, which includes its growing commercial footprint with its PlaqueIQ technology. Elucid also plans to launch several next generation plaque and FFRCT products later this year, according to a press release.

“Being at the forefront of what’s next in cardiovascular care is my passion, and I am thrilled to join Elucid at this exciting time of growth,” Burger said in a statement. “Elucid’s next generation FFRCT and plaque analysis has the potential to change how cardiovascular disease is managed and I look forward to working with the talented team to accelerate the adoption of Elucid’s groundbreaking technology.”

This marks the latest personnel move for the Boston-based med tech. 

Burger joins the company just over two months after Elucid announced Michael Lesh would join its board of directors. Currently the CEO of Syntegra, which focuses on privacy-preserved synthetic data, Lesh also serves as executive chairman of Cordance Medical. 

“We welcome Scott to our senior leadership team at this important time of growth for the company. His vast range of leadership experiences in the medical device and services space is exactly what we are looking for to take us to the next level as we increase our commercial footprint,” Elucid CEO Blake Richards said in a statement. “Scott’s knowledge and track record of success will be vital for Elucid as we launch several next generation plaque and FFRCT products in the coming months.”